Musculoskeletal Emergence: Muscle Actuation, Cartilage and Bone as Load-Bearing Jammed Matter

Skeletal muscle, cartilage, limb skeleton and bone emerge deterministically from one read-only master-gene number γ on the jamming substrate. Muscle actuation (force-frequency, length-tension, fatigue), Wolff bone remodelling as a yield threshold, and γ-ranked growth-plate order all reproduce cited signatures; a carcinogen is a barrier-lowering drive. Five physiology tests and an 18-target battery of cited-severity disease perturbations all pass.

The four measured γ order as RUNX2 1.2414 < TBX5 1.4392 < SOX9 1.4598 < MYOD1 1.4933. The disease pages are PERTURBATIONS of the passing physiology — haploinsufficiency dysplasias (a forced crossing cliff), disuse osteoporosis (the mirror of Wolff), myasthenia / Lambert-Eaton, metabolic myopathy, osteoarthritis as cartilage unjamming and achondroplasia — muscular dystrophy (reading-frame severity), muscle channelopathies (myotonia/periodic paralysis), stress fracture with fracture healing, tendinopathy, sarcopenia, osteomalacia/rickets (a mineralization ceiling) and osteolytic bone disease (myeloma/giant-cell tumour) — each with a CITED severity and honest grade. Every quantity below is regenerated deterministically (2×sha256 identical) with a reproduction path.

Sections

1. §1 Organ Emergence from Measured Gamma [V] verified
   Four organs emerge from measured master-gene γ (RUNX2 1.2414 < TBX5 1.4392 < SOX9 1.4598 < MYOD1 1.4933); γ is read-only, never fitted.
2. §2 Force-Frequency: Twitch Summation to Fused Tetanus [V] verified
   Twitches superpose into fused tetanus at 25 Hz (band 20–100) and fusion tracks 1/τ [V]; amplitude ratio uncalibrated [O].
3. §3 Length-Tension from Filament Overlap [V] verified
   Active force = filament overlap (contact number); plateau 2.05–2.25 µm, zero near 3.625 µm, matching the cited length-tension curve [V].
4. §4 Wolff Remodelling as a Yield Threshold [F] forced
   Bone density = R19 state, load = drive, spinodal 0.5324 = yield threshold; supra-threshold load flips density with hysteresis (memory) [F].
5. §5 Growth-Plate Ordering by Gamma Rank [V] verified
   γ-rank reproduces limb→cartilage→muscle (TBX5→SOX9→MYOD1) [V]; bone ossification timing is drive-gated [O].
6. §6 Muscle Fatigue as Reversible Decline [V] verified
   Sustained drive → reversible exponential force decline, τ≈59.75 s (band 20–120), recovery to 97% [V]; magnitude [O].
7. §7 Carcinogen Dose-Response in Bone and Soft Tissue [V] verified
   Carcinogen = barrier-lowering drive → Kramers RR(dose) collapses to universal convex RR=e^dose/dose* [V] across four sites; radiation anchor [L]; incidence + fusion/metabolic aetiology [O].
8. §8 Master-Gene Dosage Dysplasias (CCD, Campomelic, Holt-Oram) [F] forced threshold-shift
   Haploinsufficiency (dosage 0.5) drops the master switch below a γ-independent crossing cliff at ⅔ WT drive: CCD/RUNX2, campomelic/SOX9, Holt-Oram/TBX5 fail to cross [F]; timing [O].
9. §9 Mechanostat Disease: Osteoporosis and Osteopetrosis [F] forced
   Disuse osteoporosis = sub-threshold load lowering the dense-basin barrier; loss rate rises 1.00→2.59× with unloading [F]; osteopetrosis removes the loop's down-branch [V]; BMD [O].
10. §10 Neuromuscular Transmission: Myasthenia and Lambert-Eaton [V] verified
    MG raises the NMJ threshold → 18.4% low-frequency force decrement (>10% clinical) [V]; LEMS gives the opposite high-frequency increment (+46.7%) [V]; synaptic cause cited [L].
11. §11 Metabolic and Mitochondrial Myopathy [V] verified
    Metabolic myopathy shortens the T5 fatigue τ (60→25 s) and leaves recovery incomplete (0.835<0.95) [V]; magnitude [O].
12. §12 Osteoarthritis as Cartilage Unjamming [V] verified
    OA = cyclic-fatigue unjamming of the cartilage contact number (cited Paris/Basquin m=2): sub-threshold protected, loss convex in load+BMI [V]; absolute rate [O].
13. §13 Achondroplasia as Growth-Plate Suppression [V] verified
    Achondroplasia = FGFR3-GOF suppressive drive on the SOX9 growth-plate switch; graded shortening WT 1.00→0.09 with a cliff [V]; absolute length [O].
14. §14 Muscular Dystrophy and Sarcopenia [V] verified
    Dystrophy = contractile-contact fatigue with reading-frame severity (DMD 0.46 < BMD 0.85 < normal 1.00) [V]; sarcopenia = gradual multi-axis ageing decline [V]; absolute timeline/force [O].
15. §15 Muscle Channelopathies: Myotonia and Periodic Paralysis [V] verified
    Myotonia raises the depolarization-block threshold (1.30), periodic paralysis lowers it (0.10) vs normal (0.80) — opposite excitability signs from one FHN membrane [V]; absolute [O].
16. §16 Stress Fracture and Fracture Healing [V] verified
    Stress fracture = sub-yield cyclic bone fatigue above an endurance limit (S-N), sub-endurance protected [V]; and the fracture HEALS via T3 re-cross (0.00→1.00) unlike OA; absolute cycles [O].
17. §17 Tendinopathy as Collagen-Network Unjamming [V] verified
    Tendinopathy = cyclic-fatigue unjamming of the tendon collagen contact number (OA kernel): sub-threshold protected, loss convex in overuse [V]; absolute rate [O].
18. §18 Osteomalacia and Rickets as a Mineralization Ceiling [V] verified
    Osteomalacia/rickets = mineralization ceiling (density = matrix × mineral supply); load rescues osteoporosis but NOT osteomalacia [V]; absolute mineral density [O].
19. §19 Osteolytic Bone Disease as Osteoclast/Osteoblast Uncoupling [V] verified
    Osteolytic bone disease = osteoclast/osteoblast uncoupling: myeloma disables formation (locked lytic 0.15), the mirror of osteopetrosis; GCT's RANKL drive resorbs dense bone (→0.00) [V]; absolute lesion [O].
20. §20 Out-of-Class and Material Disease Register [O] open / routed
    Material diseases (OI, EDS/Marfan) and signatureless ones (Paget, scoliosis) carried as honest [O] (tendinopathy now §17); degenerative disc disease deferred to the existing OA/tendinopathy kernel to avoid duplication; autoimmune, crystal, pain, infection and distant-primary tumours routed to siblings via named seams (SSOT).
21. §21 Treatment Axis: Barrier Restoration [V] verified
    Treatment = disease run in reverse on a DNA-grounded switch (each organ emerged from a measured gene parameter gamma read from the human genome): restore the barrier / drive / branch / supply. 13 reversible mirror treatments restore the healthy attractor by direction (No-Tuning), each citing the real drug or load; developmental cliffs, cartilage regeneration and established-tumour chemotherapy are honest [O]. Engine hash unchanged.
22. §22 Bone and Cartilage Treatments [V] verified
    Bone / cartilage mirror treatments on the RUNX2 / SOX9 switch: loading + antiresorptive reverse osteoporosis, vitamin D refills osteomalacia, HSCT re-enables resorption (osteopetrosis), denosumab removes the osteolytic / giant-cell-tumour RANKL drive, rest + load heals stress fracture, vosoritide partially relieves achondroplasia, unloading arrests osteoarthritis (no cartilage regen [O]).
23. §23 Muscle and Neuromuscular Treatments [V] verified
    Muscle / neuromuscular mirror treatments: pyridostigmine restores the myasthenic safety factor (decrement below 10%), amifampridine raises Lambert-Eaton quantal content, mexiletine normalises channelopathy excitability, steroids + gene therapy modify muscular dystrophy (Duchenne toward Becker), resistance training partially reverses sarcopenia (ageing floor [O]), eccentric loading rebuilds tendinopathy.
24. §24 Honest Treatment Limits and Scope [O] open / scope
    Honest treatment limits (results, not failures): developmental dosage cliffs are not postnatally reversible (closed window), osteoarthritis cartilage does not regenerate (arrest-only), established-tumour chemotherapy is out of the initiation kernel’s scope while primary prevention is verified [V], and only a cofactor-responsive subset of metabolic myopathy reverses; every open item names its obstacle.
25. §25 Analgesic Axis: Three-Lever Threshold Logic [V] verified
    Non-opioid analgesia = pull one of three levers on the nociceptive THRESHOLD-CROSSING rate on the same DNA-grounded R19 barrier (L1 raise the peripheral barrier / L2 lower the noxious drive / L3 cut the central gain). Technique inherited from the VP non-opioid analgesic volume (DOI 10.5281/zenodo.20733420); the noxious drive is read from each disease kernel (single source). PASS = crossing rate falls monotonically (DIRECTION, No-Tuning). L3 central gain is a neuro/mind seam; opioid lever out of scope. Engine hash unchanged.
26. §26 L2 on Load-Bearing Disease: Analgesia-Disease Convergence [V] verified
    L2 (lower the noxious drive) on osteoarthritis, tendinopathy and stress fracture: the noxious drive is the mechanical load the disease kernel perturbs, so unloading lowers BOTH the nociceptive crossing rate AND the structural contact loss (verified by DIRECTION). Analgesia and disease-modification converge on one knob; the mirror treatment (offload) is the dominant analgesic. No-Tuning.
27. §27 L1 and the Coupled/Decoupled Discriminant [V] verified
    L1 (raise the peripheral barrier) lowers the crossing rate but leaves the lesion FLAT (structure-decoupled), while L2 lowers both (structure-coupled) -- that contrast is the decisive falsifiable discriminant. Osteolytic/myeloma bone pain is the clean L2 case where the antiresorptive that relieves the RANKL drive is both the mirror treatment and the analgesic; cancer bone pain is opioid-first-line and the opioid lever is honestly out of the non-opioid scope.
28. §28 Analgesic Limits and the Central-Gain Seam [O] open / scope
    Honest limits: L3 central gain is owned by neuro/mind and cited as a seam (not re-emerged); the opioid descending/mu lever is outside the non-opioid logic; exertional muscle pain is DIRECTION-only with no structural cross-check; neuropathic pain and fibromyalgia are routed to sibling volumes (SSOT). The axis stays strictly inside the load-bearing class -- results stated as scope, not failures.

Provenance & seams

Organ identity and developmental order are inherited from the 4D DNA Blueprint volume (measured γ); the R19 bistable switch and the jamming lattice are inherited from VP Theory; the motor command is owned by the Neural Emergence Chain. This volume is the single source only for the load-bearing dynamics and the carcinogen dose-response.